A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.

Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to the discovery of a series of potent JAK2 kinase inhibitors.

[1]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[2]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[3]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[4]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[5]  James E. Thompson.  JAK protein kinase inhibitors. , 2005, Drug news & perspectives.

[6]  G. Xu,et al.  JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia , 2005, Leukemia.

[7]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[8]  C. Seto,et al.  Divalent and trivalent α-ketocarboxylic acids as inhibitors of protein tyrosine phosphatases , 2002 .

[9]  R. Skoda.  Can we control JAK? , 2008, Blood.

[10]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[11]  S. Verstovsek,et al.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms , 2009, Expert review of anticancer therapy.

[12]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.